Want to see HK:0399 full AI Analyst Report?
Innovative Pharmaceutical Biotech (0399) AI Stock Analysis
Innovative Pharmaceutical Biotech
(HKEX:0399)
The score is primarily weighed down by weak financial performance (shrinking revenue, a major 2025 loss, ongoing cash burn, and negative equity with sizable debt). Technicals also remain bearish with price well below key moving averages and negative MACD, despite oversold signals. Valuation offers limited support due to negative earnings and no dividend yield provided.
Innovative Pharmaceutical Biotech (0399) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 164.90M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.14
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 20
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Household & Personal Products
Innovative Pharmaceutical Biotech Business Overview & Revenue Model
Company Description
Operating as an investment holding company, Innovative Pharmaceutical Biotech Limited (IPBL) primarily engages in the distribution of beauty equipment and associated products across both mainland China and Hong Kong. The firm structures its operation...
How the Company Makes Money
null
Innovative Pharmaceutical Biotech Financial Statement Overview
Summary
Very weak financial profile: multi-year revenue contraction with a steep 2025 drop, a swing to a large net loss in 2025, persistent negative operating/free cash flow, and a highly stressed balance sheet with negative equity and sizable debt.
Income Statement
14Very NegativeBalance Sheet
9Very NegativeCash Flow
16Very Negative| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.27M | 2.09M | 6.59M | 8.07M | 11.14M | 15.19M |
| Gross Profit | 328.00K | 188.00K | 840.00K | 858.00K | 1.05M | 1.41M |
| EBITDA | -15.72M | -296.99M | 317.75M | -18.82M | 228.51M | -18.81M |
| Net Income | -563.85M | -345.94M | 103.40M | -245.70M | 296.54M | -395.75M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 1.09B | 1.38B | 1.38B | 1.39B | 1.40B |
| Cash, Cash Equivalents and Short-Term Investments | 18.07M | 3.70M | 3.08M | 1.33M | 4.08M | 8.99M |
| Total Debt | 1.09B | 1.00B | 1.01B | 1.19B | 941.84M | 991.48M |
| Total Liabilities | 1.19B | 1.06B | 1.06B | 1.24B | 999.73M | 1.04B |
| Stockholders Equity | -783.77M | -681.19M | -611.51M | -795.07M | -549.37M | -595.35M |
Cash Flow | ||||||
| Free Cash Flow | 2.52M | -10.55M | -8.28M | -17.64M | -12.34M | -25.01M |
| Operating Cash Flow | 2.52M | -10.55M | -8.28M | -17.64M | -12.34M | -25.01M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -1,000 | 13.00K |
| Financing Cash Flow | 15.15M | 11.19M | 10.32M | 14.92M | 7.30M | 10.57M |
Innovative Pharmaceutical Biotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0399, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 32.25 is Neutral, neither overbought nor oversold. The STOCH value of 29.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0399.
Innovative Pharmaceutical Biotech Peers Comparison
Overall Rating
HK:660173.9Outperform
HK:236767Neutral
HK:333257Neutral
HK:988656Neutral
HK:015746Neutral- HK:039942Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6601 | 74Outperform | HKD 2.69B | 8.65 | 8.51% | 8.28% | 25.14% | 39.67% |
| HK:2367 | 67Neutral | HKD 20.76B | 10.77 | 17.22% | 3.12% | -9.65% | -25.51% |
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| HK:3332 | 57Neutral | HKD 246.26M | 6.26 | 4.67% | ― | 21.23% | 24.06% |
| HK:9886 | 56Neutral | HKD 1.10B | -15.52 | -3.87% | ― | 8.73% | 80.38% |
| HK:0157 | 46Neutral | HKD 880.92M | -15.33 | -12.81% | ― | 13.43% | 7.72% |
| HK:0399 | 42Neutral | HKD 231.21M | -0.36 | 53.52% | ― | ― | ― |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0399 | Innovative Pharmaceutical Biotech | 0.07 | -0.16 | -68.53% | |
| HK:0157 | Natural Beauty Bio-Technology | 0.44 | -0.10 | -18.52% | |
| HK:6601 | Cheerwin Group Limited | 2.02 | -0.11 | -5.31% | |
| HK:9886 | Dingdang Health Technology Group Ltd. | 0.90 | -0.19 | -17.43% | |
| HK:2367 | Giant Biogene Holding Co. Ltd. | 19.80 | -15.76 | -44.31% | |
| HK:3332 | Nanjing Sinolife United Co., Ltd. Class H | 0.15 | -0.23 | -60.00% |
Innovative Pharmaceutical Biotech Corporate Events
Starcoin Faces Prolonged Share Suspension After HKEX Review Cites Weak Operations, Heavy Liabilities
Starcoin Group Limited has been notified by the Listing Review Committee of the Hong Kong Stock Exchange that its decision to suspend trading in the company’s shares will be upheld. The committee found that Starcoin had failed to maintain suffi...
Starcoin Secures Injunction as HKEX Panel Upholds Trading Suspension Decision
Starcoin Group Limited has disclosed that the Listing Review Committee of the Hong Kong Stock Exchange upheld an earlier decision to suspend trading in its shares, citing the company’s failure to maintain sufficient operations and assets to jus...
Starcoin Advances Bond Restructuring and Funding Plans After Audit Disclaimer
Starcoin Group Limited has issued an update on efforts to address a prior audit disclaimer of opinion related to its ability to continue as a going concern, outlining progress on bond restructuring, capital raising, and cost controls. The company rem...
Starcoin Group Plans Debt-Equity Deal to Cut Liabilities and Add Strategic Investor
Starcoin Group Limited has signed a memorandum of understanding with Hong Kong-incorporated Marvel Nice Limited for a possible share subscription, following Marvel Nice’s intended acquisition of HK$715 million in convertible bonds previously is...
Starcoin Group Signs Strategic Biotech Cooperation MOU With Huamei Haibo
Starcoin Group Limited has signed a memorandum of understanding with Chongqing-based Huamei Haibo Biotechnology to pursue strategic cooperation spanning equity investment, asset restructuring, Web3.0 healthcare, joint business development, financing,...
Starcoin Secures Exclusive Rights to Tokenize Brazilian Gold Mine Assets
Starcoin Group Limited has entered into an exclusive management agreement via its subsidiary Starcoin Hong Kong Limited with Brazil-based Nhandu Parkent Mineracao and U.S.-incorporated Goldcoin Global Asset Management to tokenize real-world assets fr...
Starcoin Expands De-SPAC Talks With Newbridge and Conflux to Bolster Blockchain Push
Starcoin Group Limited has signed a new memorandum of understanding with NASDAQ-listed Newbridge Acquisition Limited and Conflux Foundation to explore a potential de-SPAC transaction involving the group, Conflux and their respective assets or busines...
Starcoin Group Explores NASDAQ De-SPAC Deal With Newbridge Acquisition
Starcoin Group Limited has signed a memorandum of understanding with Newbridge Acquisition Limited, a NASDAQ-listed special purpose acquisition company, to explore a potential de-SPAC transaction involving the group and its assets or businesses. The...
Starcoin Extends Convertible Bond Deadline and Delays Key Shareholder Circular
Starcoin Group Limited has agreed with Extrawell Pharmaceutical Holdings Limited to extend the long stop date for fulfilling conditions under the fourth deed of amendment relating to its outstanding convertible bonds from 31 March 2026 to 30 June 202...
Starcoin Partners with China Digital Finance on Gold‑Backed Tokenization Push
Starcoin Group Limited has signed a strategic cooperation framework agreement with China International Digital Finance Group Limited to develop a gold‑backed real‑world asset tokenization project. Under the arrangement, China Digital Fina...
Starcoin Group Seeks Review of HKEX Ruling on Insufficient Operations
Starcoin Group Limited has disclosed that the Hong Kong stock exchange has determined the company failed to maintain a sufficient level of operations as required under listing rules, a finding previously upheld by the Listing Committee. The group, wh...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 01, 2026